Skip to content
Screener

Regeneron Pharmaceuticals REGN Gross margin

Discontinued — last reported Q4 '19

Gross margin at other companies

Merck & Co. logo
Merck & Co.MRK
73.9%-2.5pp
Amgen logo
AmgenAMGN
68.3%+5.3pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
100%+31.2pp
Glaukos logo
GlaukosGKOS
61%-15.4pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
87.2%-3.4pp
Regenxbio logo
RegenxbioRGNX
59.7%+1.0pp

Other financials

Income statement

See full
Revenue$4.3B+16.7%
Operating income$1.3B+19.8%
Net income$1.3B-6.8%
EPS (diluted)$12.23-4.5%

Balance sheet

See full
Cash & equivalents$2.5B+22.3%
Total debt$2.7B+0.1%
Total equity$31.7B+5.9%
Total assets$41.7B+9.2%

Cash flow

See full
Operating cash flow$813.0M-29.0%
CapEx$240.2M+9.7%
Free cash flow$572.8M-38.1%

Valuation

See full
Market cap$78.52B+29.6%
Enterprise value$78.76B+28.6%
P/E18.1×+4.6×
P/S5.1×+0.8×

Profitability

See full
Operating margin24.7%-2.3pp
Net margin27.9%-3.5pp
FCF margin24.2%-2.9pp

Returns & leverage

See full
Return on equity14%-1.3pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.3×

Where this comes from

Calculated from Regeneron Pharmaceuticals’s reported figures.

gross profit/total revenue=94.9%

Based on trailing twelve months.

The source filing: Regeneron Pharmaceuticals’s 10-Q, filed November 4, 2021. Open the filing →

Filed
Nov 3, 2021, 8:00 PM EDT
Fiscal quarter
Q3 FY2021
Calendar quarter
Q3 2021
Accession
0001804220-21-000033

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.